Can a new platform slash ER wait times? huge trial aims to find out

NCT ID NCT04789902

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This large trial tests a platform called SurgeCon, designed to improve how emergency departments (EDs) manage patient flow. The goal is to reduce wait times, shorten the time to see a doctor, and lower the number of patients who leave without being seen. Over 400,000 people visiting four EDs in Canada will be included, and the results could help make emergency care more efficient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SurgeCon (a quality improvement platform including workflow restructuring, patient-centric environment, and e-health management)
What this could lead to
If successful, this could provide a proven way to cut emergency department wait times and reduce the number of patients who leave without being seen.
What could go wrong
This is a pragmatic trial testing a complex intervention across multiple sites, so results may vary by location. It is not a drug or device trial, so the impact is limited to operational improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EMERGENCY DEPARTMENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Emergencies

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Burin Peninsula Healthcare Centre

    Burin, Newfoundland and Labrador, A0E1E0, Canada

  • Dr. G.B. Cross Memorial Hospital

    Clarenville, Newfoundland and Labrador, A5A1K3, Canada

  • Health Sciences Centre

    St. John's, Newfoundland and Labrador, A1B 3V6, Canada

  • St. Clare's Mercy Hospital

    St. John's, Newfoundland and Labrador, A1C5B8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.